- Advances in the biology and therapy of chronic myeloid leukemia: proceedings from the 6th Post-ASH International Chronic Myeloid Leukemia and Myeloproliferative Neoplasms WorkshopRichard A Van Etten
Molecular Oncology Research Institute, Tufts Medical Center, Boston, MA 02111, USA
Leuk Lymphoma 54:1151-8. 2013..A report summarizing the pertinent advances in MPN has been published separately...
- The Ph-positive and Ph-negative myeloproliferative neoplasms: some topical pre-clinical and clinical issuesRichard A Van Etten
Division of Hematology Oncology, Molecular Oncology Research Institute, Tufts Medical Center, Boston, MA 02111, USA
Haematologica 96:590-601. 2011..Finally, the clinical role of the new JAK2- and BCR-ABL1-inhibitors is considered. Much further progress is likely in several of these areas soon...
- BCL6: a novel target for therapy of Ph+ B cell acute lymphoblastic leukemiaRichard A Van Etten
Molecular Oncology Research Institute, Division of Hematology Oncology, Tufts Medical Center, Boston, MA 02111, USA
Cancer Cell 20:3-5. 2011..In a recent issue of Nature, Duy et al. describe a novel role for BCL6 at the center of a transcriptional network in Ph(+) acute lymphoblastic leukemia cells that modulates their leukemogenicity and response to kinase inhibitors...